Advertisement
Screener

TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) Graph

TNXP Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $13.54M; Cost of revenue $703.00K; Research and development $19.42M; Selling, general and administrative $35.96M.
  • 2026-03-31: Revenue $6.88M; Cost of revenue $1.58M; Research and development $18.21M; Selling, general and administrative $28.62M.
  • 2025-12-31: Revenue $5.39M*; Cost of revenue $1.06M*; Research and development $16.94M*; Selling, general and administrative $35.68M*.
  • 2025-09-30: Revenue $3.29M; Cost of revenue $1.37M; Research and development $9.29M; Selling, general and administrative $25.70M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

TNXP revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Tonmya$10.95MTosymra$594.00KZembrace Symtouch$2.00MRevenue$13.54MCost of revenue$703.00KOperating income-$42.54MOther income, net-$49.00KResearch & development$19.42MSelling, general& administrative$35.96MNet income-$40.55M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesNet income
2026-06-30$13.54M$703.00K$19.42M$35.96M(m)-$40.55M
2026-03-31$6.88M$1.58M$18.21M$28.62M(m)-$40.19M
2025-12-31$5.39M*$1.06M*$16.94M*$35.68M*(m)-$46.91M*
2025-09-30$3.29M$1.37M$9.29M$25.70M(m)-$32.01M
2025-06-30$2.00M$3.27M$10.82M$16.20M(m)-$28.27M
2025-03-31$2.43M$943.00K$7.44M$10.10M(m)-$16.83M
2024-09-30$2.82M$1.55M$9.11M$7.71M(m)-$14.21M
2024-06-30$2.21M$3.37M$9.70M$7.50M(m)-$78.78M
2024-03-31$2.48M$1.66M$12.86M$9.31M(m)-$14.94M
2023-09-30$3.99M$2.37M$21.05M$8.71M(m)-$27.98M
2023-06-30(m)(m)$21.98M$7.03M(m)-$28.36M
2023-03-31(m)(m)$26.51M$7.39M(m)-$33.01M
2022-09-30(m)(m)$22.20M$7.39M(m)-$28.98M
2022-06-30(m)(m)$16.58M(m)(m)-$23.14M
2022-03-31(m)(m)$18.42M(m)(m)-$26.42M
2021-09-30(m)(m)$13.08M(m)(m)-$18.53M
2021-06-30(m)(m)$18.13M(m)(m)-$23.55M
2021-03-31(m)(m)$15.33M(m)(m)-$20.65M
2020-09-30(m)(m)$8.81M(m)(m)-$11.99M
2020-06-30(m)(m)$10.57M(m)(m)-$14.18M
2020-03-31(m)(m)$4.68M(m)(m)-$7.27M
2019-09-30(m)(m)$5.05M(m)(m)-$7.84M
2019-06-30(m)(m)$3.55M(m)(m)-$5.84M
2019-03-31(m)(m)$3.90M(m)(m)-$6.23M
2018-09-30(m)(m)$3.26M(m)(m)-$5.48M
2018-06-30(m)(m)$4.07M(m)(m)-$6.09M
2018-03-31(m)(m)$5.17M(m)(m)-$6.93M
2017-09-30(m)(m)$3.91M(m)(m)-$5.79M
2017-06-30(m)(m)$2.81M(m)(m)-$4.78M
2017-03-31(m)(m)$2.99M(m)(m)-$5.06M
2016-09-30(m)(m)$5.47M(m)(m)-$7.58M
2016-06-30(m)(m)$7.52M(m)(m)-$9.81M
2016-03-31(m)(m)$10.67M(m)$14.01M-$13.98M
2015-12-31(m)(m)(m)(m)$13.40M*-$13.36M
2015-09-30(m)(m)$10.31M(m)$13.28M-$13.25M
2015-06-30(m)(m)$8.87M(m)$11.78M-$11.76M
2015-03-31(m)(m)$6.83M(m)$9.70M-$9.68M
2014-12-31(m)(m)(m)(m)(m)-$8.99M
2014-09-30(m)(m)$5.22M(m)$7.43M-$7.42M
2014-06-30(m)(m)$4.08M(m)$6.05M-$6.04M
2014-03-31(m)(m)$3.55M(m)$5.17M-$5.16M
2013-09-30(m)(m)$1.64M(m)$3.09M-$3.09M
2013-06-30(m)(m)$944.00K(m)$2.09M-$2.09M
2013-03-31(m)(m)$741.00K(m)$2.00M-$2.00M
2012-09-30(m)(m)$658.14K(m)$1.73M-$1.73M
2012-06-30(m)(m)$658.14K(m)$1.73M-$1.73M
2012-03-31(m)(m)$397.63K(m)$1.16M-$2.01M
2011-09-30(m)(m)$492.02K(m)$1.01M-$1.01M
2011-06-30(m)(m)$63.01K(m)$355.83K-$355.81K
2011-03-31(m)(m)$79.46K(m)$513.68K-$513.66K
2010-09-30(m)(m)(m)(m)(m)-$3.69K
2010-06-30(m)(m)(m)(m)(m)-$2.40K

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesNet income
2026-06-30$20.42M$2.28M$37.63M$64.58M(m)-$80.75M
2025-06-30$4.43M$4.21M$18.26M$26.31M(m)-$45.10M
2024-06-30$4.69M$5.03M$22.56M$16.81M(m)-$93.72M
2023-06-30(m)(m)$48.49M$14.42M(m)-$61.36M
2022-06-30(m)(m)$35.00M(m)(m)-$49.56M
2021-06-30(m)(m)$33.46M(m)(m)-$44.21M
2020-06-30(m)(m)$15.25M(m)(m)-$21.45M
2019-06-30(m)(m)$7.45M(m)(m)-$12.07M
2018-06-30(m)(m)$9.24M(m)(m)-$13.02M
2017-06-30(m)(m)$5.80M(m)(m)-$9.84M
2016-06-30(m)(m)$18.19M(m)(m)-$23.78M
2015-06-30(m)(m)$15.70M(m)$21.48M-$21.44M
2014-06-30(m)(m)$7.63M(m)$11.22M-$11.21M
2013-06-30(m)(m)$1.69M(m)$4.09M-$4.09M
2012-06-30(m)(m)$1.23M(m)$3.01M-$5.09M
2011-06-30(m)(m)$142.47K(m)$869.51K-$869.47K
2010-06-30(m)(m)(m)(m)(m)-$8.22K

Revenue and expense 7 month

Period endNet income
2007-12-31-$537.00K

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesNet income
2025-09-30$7.72M$5.58M$27.55M$52.01M(m)-$77.11M
2024-09-30$7.51M$6.58M$31.68M$24.52M(m)-$107.93M
2023-09-30$3.99M$2.37M$69.53M$23.13M(m)-$89.34M
2022-09-30(m)(m)$57.20M$22.16M(m)-$78.54M
2021-09-30(m)(m)$46.54M(m)(m)-$62.73M
2020-09-30(m)(m)$24.06M(m)(m)-$33.44M
2019-09-30(m)(m)$12.50M(m)(m)-$19.91M
2018-09-30(m)(m)$12.50M(m)(m)-$18.50M
2017-09-30(m)(m)$9.71M(m)(m)-$15.63M
2016-09-30(m)(m)$23.65M(m)(m)-$31.36M
2015-09-30(m)(m)$26.01M(m)$34.76M-$34.69M
2014-09-30(m)(m)$12.84M(m)$18.65M-$18.63M
2013-09-30(m)(m)$3.32M(m)$7.18M-$7.18M
2012-09-30(m)(m)$1.88M(m)$4.75M-$6.82M
2011-09-30(m)(m)$634.50K(m)$1.88M-$1.88M
2010-09-30(m)(m)(m)(m)(m)-$11.91K

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesNet income
2025-12-31$13.11M$6.64M$44.49M$87.68M(m)-$124.02M
2024-12-31$10.09M$7.76M$39.97M$40.10M(m)-$130.04M
2023-12-31$7.77M$4.74M$86.66M$34.75M(m)-$116.66M
2022-12-31(m)(m)$81.88M$30.21M(m)-$110.22M
2021-12-31(m)(m)$68.84M(m)(m)-$92.29M
2020-12-31(m)(m)$36.16M(m)(m)-$50.46M
2019-12-31(m)(m)$18.19M(m)(m)-$28.62M
2018-12-31(m)(m)$17.56M(m)(m)-$26.09M
2017-12-31(m)(m)$13.34M(m)(m)-$21.12M
2016-12-31(m)(m)$28.53M(m)(m)-$38.84M
2015-12-31(m)(m)$35.50M(m)$48.16M-$48.05M
2014-12-31(m)(m)$18.62M(m)$27.66M-$27.62M
2013-12-31(m)(m)$4.65M(m)$10.89M-$10.88M
2012-12-31(m)(m)$2.58M(m)$6.66M-$9.45M
2011-12-31(m)(m)$1.16M(m)$3.38M-$3.47M
2010-12-31(m)(m)$584.30K(m)$1.93M-$1.96M
2009-12-31(m)(m)(m)(m)(m)-$221.00K
2008-12-31(m)(m)(m)(m)(m)-$202.00K

Similar stocks

Stock NameCountryMarket CapPE Ratio
Minerva Neurosciences, Inc. (NERV)United States$0.165B-0.66
ADC Therapeutics SA (ADCT)$0.163B-1.39
LIFECORE BIOMEDICAL, INC. DE (LFCR)United States$0.163B-8.50
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
Annexon, Inc. (ANNX)United States$0.147B-4.22
PepGen Inc. (PEPG)United States$0.186B-1.73
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91